Kornitzer Capital Management Inc. KS Increases Stock Holdings in Option Care Health, Inc. (NASDAQ:OPCH)

Kornitzer Capital Management Inc. KS raised its stake in Option Care Health, Inc. (NASDAQ:OPCH - Free Report) by 2.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 444,095 shares of the company's stock after acquiring an additional 10,900 shares during the quarter. Kornitzer Capital Management Inc. KS owned approximately 0.26% of Option Care Health worth $10,303,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. UMB Bank n.a. increased its stake in Option Care Health by 41.7% during the 4th quarter. UMB Bank n.a. now owns 1,176 shares of the company's stock valued at $27,000 after purchasing an additional 346 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its position in Option Care Health by 3,362.8% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 1,489 shares of the company's stock valued at $47,000 after buying an additional 1,446 shares during the period. International Assets Investment Management LLC raised its position in Option Care Health by 3,029.7% in the third quarter. International Assets Investment Management LLC now owns 2,848 shares of the company's stock worth $91,000 after acquiring an additional 2,757 shares during the period. Quarry LP boosted its stake in Option Care Health by 327.7% in the third quarter. Quarry LP now owns 3,430 shares of the company's stock valued at $107,000 after acquiring an additional 2,628 shares during the last quarter. Finally, Blue Trust Inc. grew its position in shares of Option Care Health by 16.9% during the 4th quarter. Blue Trust Inc. now owns 4,703 shares of the company's stock valued at $109,000 after acquiring an additional 681 shares during the period. Institutional investors own 98.05% of the company's stock.

Option Care Health Price Performance

Shares of OPCH traded down $0.39 during mid-day trading on Friday, hitting $32.00. 1,771,776 shares of the stock were exchanged, compared to its average volume of 1,711,993. The company has a market cap of $5.45 billion, a PE ratio of 26.89, a price-to-earnings-growth ratio of 2.30 and a beta of 1.35. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.32 and a current ratio of 1.73. The firm has a 50-day moving average of $27.54 and a two-hundred day moving average of $27.97. Option Care Health, Inc. has a 52-week low of $21.39 and a 52-week high of $34.63.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the stock. UBS Group assumed coverage on shares of Option Care Health in a report on Thursday, December 5th. They issued a "neutral" rating and a $26.00 price target on the stock. Bank of America raised Option Care Health from a "neutral" rating to a "buy" rating and increased their target price for the company from $26.00 to $33.00 in a research note on Monday, January 13th. Jefferies Financial Group upgraded shares of Option Care Health from a "hold" rating to a "buy" rating and boosted their price objective for the stock from $26.00 to $35.00 in a report on Thursday, January 23rd. The Goldman Sachs Group lowered Option Care Health from a "buy" rating to a "neutral" rating and lowered their target price for the company from $38.00 to $27.00 in a research note on Monday, November 4th. Finally, JMP Securities reissued a "market outperform" rating and set a $30.00 price target (down previously from $31.00) on shares of Option Care Health in a research report on Friday, January 10th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $32.25.

Option Care Health Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.